27535101|t|Intestinal transport of HDND-7, a novel hesperetin derivative, in in vitro MDCK cell and in situ single-pass intestinal perfusion models
27535101|a|1. Hesperetin (HDND) possesses extensive bioactivities, however, its poor solubility and low bioavailability limit its application. HDND-7, a derivative of HDND, has better solubility and high bioavailability. In this study, we investigated the intestinal absorption mechanisms of HDND-7. 2. MDCK cells were used to examine the transport mechanisms of HDND-7 in vitro, and a rat in situ intestinal perfusion model was used to characterize the absorption of HDND-7. The concentration of HDND-7 was determined by HPLC. 3. In MDCK cells, HDND-7 was effectively absorbed in a concentration - dependent manner in both directions. Moreover, HDND-7 showed pH - dependent and TEER - independent transport in both directions. The transport of HDND-7 was significantly reduced at 4 Â°C or in the presence of NaN3. Furthermore, the efflux of HDND-7 was apparently reduced in the presence of MRP2 inhibitors MK-571 or probenecid. However, P-gp inhibitor verapamil had no effect on the transport of HDND-7. The in situ intestinal perfusion study indicated HDND-7 was well-absorbed in four intestinal segments. Furthermore, MRP2 inhibitors may slightly increase the absorption of HDND-7 in jejunum. 4. In summary, all results indicated that HDND-7 might be absorbed mainly by passive diffusion via transcellular pathway, MRP2 but P-gp may participate in the efflux of HDND-7.
27535101	0	10	Intestinal	T017	UMLS:C0021853
27535101	11	20	transport	T038	UMLS:C0005528
27535101	24	30	HDND-7	T103	UMLS:C0019392
27535101	40	50	hesperetin	T103	UMLS:C0019392
27535101	75	84	MDCK cell	T017	UMLS:C0598829
27535101	89	129	in situ single-pass intestinal perfusion	T058	UMLS:C0031006
27535101	130	136	models	T170	UMLS:C3161035
27535101	140	150	Hesperetin	T103	UMLS:C0019392
27535101	152	156	HDND	T103	UMLS:C0019392
27535101	269	275	HDND-7	T103	UMLS:C0019392
27535101	293	297	HDND	T103	UMLS:C0019392
27535101	382	403	intestinal absorption	T038	UMLS:C0021826
27535101	418	424	HDND-7	T103	UMLS:C0019392
27535101	429	439	MDCK cells	T017	UMLS:C0598829
27535101	465	485	transport mechanisms	T038	UMLS:C0005528
27535101	489	495	HDND-7	T103	UMLS:C0019392
27535101	512	515	rat	T204	UMLS:C0034693
27535101	516	544	in situ intestinal perfusion	T058	UMLS:C0031006
27535101	594	600	HDND-7	T103	UMLS:C0019392
27535101	623	629	HDND-7	T103	UMLS:C0019392
27535101	648	652	HPLC	T058	UMLS:C0008562
27535101	660	670	MDCK cells	T017	UMLS:C0598829
27535101	672	678	HDND-7	T103	UMLS:C0019392
27535101	750	760	directions	T082	UMLS:C0439755
27535101	772	778	HDND-7	T103	UMLS:C0019392
27535101	812	823	independent	T033	UMLS:C1299583
27535101	824	833	transport	T038	UMLS:C0005528
27535101	842	852	directions	T082	UMLS:C0439755
27535101	858	867	transport	T038	UMLS:C0005528
27535101	871	877	HDND-7	T103	UMLS:C0019392
27535101	922	930	presence	T033	UMLS:C0150312
27535101	934	938	NaN3	T103	UMLS:C0074721
27535101	957	963	efflux	T038	UMLS:C1512072
27535101	967	973	HDND-7	T103	UMLS:C0019392
27535101	1004	1012	presence	T033	UMLS:C0150312
27535101	1016	1020	MRP2	T103	UMLS:C0525410
27535101	1032	1038	MK-571	T103	UMLS:C0128634
27535101	1042	1052	probenecid	T103	UMLS:C0033209
27535101	1063	1077	P-gp inhibitor	T103	UMLS:C3898062
27535101	1078	1087	verapamil	T103	UMLS:C0042523
27535101	1109	1118	transport	T038	UMLS:C0005528
27535101	1122	1128	HDND-7	T103	UMLS:C0019392
27535101	1134	1162	in situ intestinal perfusion	T058	UMLS:C0031006
27535101	1179	1185	HDND-7	T103	UMLS:C0019392
27535101	1212	1222	intestinal	T017	UMLS:C0021853
27535101	1246	1250	MRP2	T103	UMLS:C0525410
27535101	1302	1308	HDND-7	T103	UMLS:C0019392
27535101	1312	1319	jejunum	T017	UMLS:C0022378
27535101	1363	1369	HDND-7	T103	UMLS:C0019392
27535101	1420	1441	transcellular pathway	T038	UMLS:C2936269
27535101	1443	1447	MRP2	T103	UMLS:C0525410
27535101	1452	1456	P-gp	T103	UMLS:C0069906
27535101	1480	1486	efflux	T038	UMLS:C1512072
27535101	1490	1496	HDND-7	T103	UMLS:C0019392